Literature DB >> 689732

Antibody-mediated recovery from subcutaneous herpes simplex virus type 2 infection.

J E Oakes, H Rosemond-Hornbeak.   

Abstract

Young adult mice infected with 3 X 10(6) plaque-forming units of herpes simplex virus type 2 (HSV-2) died within 9 to 12 days after spread of the virus from the sites of infection to the spinal cord and brain. Administration of HSV-2-neutralizing antisera prepared in syngenic mice or in rabbits inhibited spread of the virus from the footpad of infected animals and prevented death. A single intraperitoneal inoculum of antiserum (virus-neutralizing titer of 1:128) was effective in protecting mice when the antiserum was given at 8 to 48 h, but not at 72 h, after virus inoculation. Immune sera absorbed with HSV-2-infected cells no longer protected mice from subcutaneous infection, whereas absorption with noninfected cells had no effect. Thus, HSV-2-specific antibodies appeared to be responsible for the protection observed. If the mice were given a sublethal dose of irradiation (390 rads) at 24 h before antibody transfer, protection was no longer obtained. This suggested that the mechanism of protection probably was not solely due to in vivo neutralization of virus, but required the participation of a radiosensitive component which has not yet been defined.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 689732      PMCID: PMC422022          DOI: 10.1128/iai.21.2.489-495.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Immunological response restricts number of cells in sensory ganglia infected with herpes simplex virus.

Authors:  M A Walz; H Yamamoto; A L Notkins
Journal:  Nature       Date:  1976-12-09       Impact factor: 49.962

2.  The elimination of herpes simplex plaques by antibody and the emergence of resistant strains.

Authors:  P R Pavan; F A Ennis
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

3.  Genome location of polyadenylated transcripts of herpes simplex virus type 1 and type 2 DNA.

Authors:  J E Oakes; R W Hyman; F Rapp
Journal:  Virology       Date:  1976-11       Impact factor: 3.616

4.  Immunoglobulin binding to herpes virus-induced Fc receptors inhibits virus growth.

Authors:  J Costa; A S Rabson; C Yee; T S Tralka
Journal:  Nature       Date:  1977-09-15       Impact factor: 49.962

Review 5.  Herpes simplex infections in hematologic malignancies.

Authors:  S A Muller; E C Herrmann; R K Winkelmann
Journal:  Am J Med       Date:  1972-01       Impact factor: 4.965

6.  Herpesvirus hominis infection in patients with myeloproliferative and lymphoproliferative disorders.

Authors:  D L Aston; A Cohen; M A Spindler
Journal:  Br Med J       Date:  1972-11-25

7.  Macrophages and age-dependent resistance to Herpes simplex virus in mice.

Authors:  M S Hirsch; B Zisman; A C Allison
Journal:  J Immunol       Date:  1970-05       Impact factor: 5.422

8.  Human monocyte-macrophage-mediated antibody-dependent cytotoxicity to herpes simplex virus-infected cells.

Authors:  S Kohl; S E Starr; J M oleske; S L Shore; R B Ashman; A J Nahmias
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

9.  The mononuclear cell in human blood which mediates antibody-dependent cellular cytotoxicity to virus-infected target cells. I. Identification of the population of effector cells.

Authors:  S L Shore; F M Melewicz; D S Gordon
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

10.  THE PATHOGENESIS OF HERPES VIRUS ENCEPHALITIS. II. A CELLULAR BASIS FOR THE DEVELOPMENT OF RESISTANCE WITH AGE.

Authors:  R T JOHNSON
Journal:  J Exp Med       Date:  1964-09-01       Impact factor: 14.307

View more
  24 in total

1.  Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice.

Authors:  Sarat K Dalai; Lesley Pesnicak; Georgina F Miller; Stephen E Straus
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

2.  Prevention and treatment of experimental herpes simplex virus encephalitis with human immune serum globulin.

Authors:  K S Erlich; R D Dix; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  Antigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production.

Authors:  S D Marlin; S L Highlander; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

4.  Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing).

Authors:  H W Virgin; R Bassel-Duby; B N Fields; K L Tyler
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

5.  Monoclonal antibodies suppress replication of herpes simplex virus type 1 in trigeminal ganglia.

Authors:  J E Oakes; R N Lausch
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

6.  Initial herpes simplex virus type 1 infection prevents ganglionic superinfection by other strains.

Authors:  Y M Centifanto-Fitzgerald; E D Varnell; H E Kaufman
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

7.  Immune responses in mice against herpes simplex virus: mechanisms of protection against facial and ganglionic infections.

Authors:  H J Zweerink; D Martinez; R J Lynch; L W Stanton
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

8.  Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.

Authors:  N Balachandran; S Bacchetti; W E Rawls
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

9.  Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.

Authors:  J Glorioso; C H Schröder; G Kumel; M Szczesiul; M Levine
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

10.  Virus-specific antibodies in sera from patients with genital herpes simplex virus infection.

Authors:  H J Zweerink; L Corey
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.